content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on June 21, 2023</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-257723</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND POST-EFFECTIVE AMENDMENT NO. 1 TO:</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 REGISTRATION STATEMENT NO. 333-257723</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RELMADA THERAPEUTICS, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its
  Charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45-5401931</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
      or other Jurisdiction of</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S
      Employer</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
      or Organization)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
      Number)</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2222 Ponce de Leon Blvd.,&nbsp;Floor 3</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Coral Gables,&nbsp;FL</B></P></TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>33134</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
      of Principal Executive Offices)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
      Code)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RELMADA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE
  PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full Title of the Plans)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sergio Traversa<BR>
  Chief Executive Officer<BR>
  2222 Ponce de Leon Blvd.,&nbsp;Floor 3</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Coral Gables,&nbsp;FL</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
  <B>Phone: (212) 547-9591</B><BR>
  (Name, Address and Telephone Number of Agent for Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copy to:</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gregory Sichenzia, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Barrett DiPaolo, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sichenzia Ross Ference LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1185 Avenue of the Americas</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10036</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+1-212-930-9700</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
  the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging
  growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller reporting
  company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="white-space: nowrap; width: 21%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
      accelerated filer</FONT></TD>
      <TD STYLE="white-space: nowrap; width: 34%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="white-space: nowrap; width: 27%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
      filer</FONT></TD>
      <TD STYLE="white-space: nowrap; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
      filer</FONT></TD>
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
      reporting company</FONT></TD>
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
      Growth Company</FONT></TD>
      <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
  indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
  financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement on Form S-8 is being
  filed by Relmada Therapeutics, Inc. (the &ldquo;Company&rdquo;), pursuant to General Instruction E to the Form S-8 Registration Statement
  under the Securities Act of 1933, as amended, to register an additional 6,400,000 shares of the Company&rsquo;s common stock, par
  value $0.001 per share (the &ldquo;Common Stock&rdquo;) issued or issuable pursuant to awards under the Company&rsquo;s 2021 Equity Incentive
  Plan, as amended (the &ldquo;2021 Plan);</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1,500,000 shares of Common Stock issued or issuable
  under the 2021 Plan have been previously registered pursuant to the Company&rsquo;s Registration Statement on Form S-8 (File No. 333-257723),
  filed with the Securities and Exchange on July 6, 2021, and the information contained therein is incorporated herein by reference.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration also includes a reoffer prospectus
  pursuant to Form S-3 (in accordance with Section C of the General Instructions to the Form S-8), which covers reoffers and resales of
  &ldquo;restricted securities&rdquo; and/or &ldquo;control securities&rdquo; (as such terms are defined in Section&nbsp;C of the General
  Instructions to Form S-8). This reoffer prospectus relates to offers and resales by directors and executive officers of shares of Common
  Stock and shares of Common Stock that are issuable upon the exercise of awards granted by the Company pursuant to the 2021 Plan. This
  reoffer prospectus may be used by the Selling Stockholders holders for reoffers and resales on a continuous or delayed basis in the future
  shares of Common Stock issued pursuant to the 2021 Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second part of this Registration Statement
  contains information required in the Registration Statement pursuant to Part&nbsp;II of Form S-8.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.</B>&nbsp;<B>Plan Information</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The documents containing the information
  specified in Part I of Form S-8 will be sent or given to each recipient of a grant under the 2021 Plan (the &ldquo;Recipient&rdquo;)
  in accordance with Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and
  Exchange Commission (the &ldquo;Commission&rdquo; or the &ldquo;SEC&rdquo;) and the instructions to Form S-8, such documents are not
  being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant
  to Rule 424 under the Securities Act.&nbsp;Such documents and the documents incorporated by reference into this Registration
  Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the
  requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2. Registrant Information and Employee
  Plan Annual Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each Recipient a written statement
  advising of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents
  are incorporated by reference in this Section 10(a) prospectus) and of documents required to be delivered pursuant to Rule 428(b) under
  the Securities Act without charge and upon written or oral request by contacting:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Relmada Therapeutics, Inc.<BR>
  <BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2222 Ponce de Leon Blvd.,&nbsp;Floor 3</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Coral Gables,&nbsp;FL 33134</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: 212-547-9591</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Investor Relations</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>REOFFER PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6,020,608 Shares</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issued or issuable under certain awards</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>granted under the 2021 Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus relates to 6,020,608
  shares of our common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;) that may be reoffered or resold, from time to
  time, by certain stockholders identified herein in the section entitled &ldquo;Selling Stockholders.&rdquo; Such shares have been or
  may be acquired in connection with awards granted under the Relmada Therapeutics, Inc. (the &ldquo;Company&rdquo;) 2021 Equity Incentive
  Plan (as amended, the &ldquo;2021 Plan&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders, or their pledgees,
  donees, transferees or other successors-in-interest, may offer and sell their shares on the Nasdaq Global Select Market, or such other
  stock market or exchange on which our Common Stock may be listed or quoted, in negotiated transactions or otherwise, at market prices
  prevailing at the time of the sale, at prices related to prevailing market prices or at prices otherwise negotiated (see &ldquo;Plan
  of Distribution&rdquo; starting on page 9 of this prospectus). We will receive no part of the proceeds from sales made under this reoffer
  prospectus. The Selling Stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection
  with the registration and offering and not borne by the Selling Stockholders will be borne by us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus has been prepared for
  the purposes of registering the shares under the Securities Act to allow for future sales by Selling Stockholders on a continuous or
  delayed basis to the public without restriction. We have not entered into any underwriting arrangements in connection with the sale of
  the shares covered by this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves certain
  risks. See &ldquo;Risk Factors&rdquo; beginning on page 5 and the risk factors in our most recent Annual Report on Form 10-K, which are
  incorporated by reference herein, as well as in any other more recently filed annual, quarterly or current reports and, if any, in the
  relevant prospectus supplement. We urge you to carefully read this prospectus and the accompanying prospectus supplement, together with
  the documents we incorporate by reference, describing the terms of these securities before investing.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Common Stock is quoted on the Nasdaq Global Select
  Market under the symbol &ldquo;RLMD.&rdquo; The last reported sale price of our Common Stock on the Nasdaq Global Select Market on June
  16, 2023, was $2.60 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
  nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
  Any representation to the contrary is a criminal offense.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this reoffer prospectus is June 21, 2023</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 90%; text-align: justify">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary
      Statement Regarding Forward-Looking Statements</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
      Summary</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
      Factors</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
      of Proceeds</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
      Stockholders</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan
      of Distribution</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
      Matters</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
      of Certain Documents by Reference</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
      You can Find Additional Information</FONT></A></TD>
      <TD STYLE="vertical-align: top; text-align: center">11</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">i</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and any accompanying prospectus
  supplement and the documents incorporated by reference herein may contain forward looking statements that involve risks and uncertainties.
  All statements other than statements of historical fact contained in this prospectus and any accompanying prospectus supplement and the
  documents incorporated by reference herein, including statements regarding future events, our future financial performance, business
  strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify
  forward-looking statements by terminology including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo;
  &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
  &ldquo;predicts,&rdquo; &ldquo;should,&rdquo; or &ldquo;will&rdquo; or the negative of these terms or other comparable terminology. Although
  we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy.
  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined
  under &ldquo;Risk Factors&rdquo; or elsewhere in this prospectus and the documents incorporated by reference herein, which may cause
  our or our industry&rsquo;s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking
  statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time
  to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the
  extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any
  forward-looking statements.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based these forward-looking
  statements largely on our current expectations and projections about future events and financial trends that we believe may affect
  our financial condition, results of operations, business strategy, short term and long term business operations, and financial
  needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ
  materially from those reflected in the forward looking statements. Factors that could cause or contribute to such differences
  include, but are not limited to, those discussed in this prospectus, and in particular, the risks discussed below and under the
  heading &ldquo;Risk Factors&rdquo; and those discussed in other documents we file with the Securities and Exchange Commission (the
  &ldquo;Commission&rdquo; or the &ldquo;SEC&rdquo;). This prospectus should be read in conjunction with the consolidated financial
  statements as of and for the years ended December 31, 2022 and December 31, 2021, and related notes thereto, incorporated by
  reference into this prospectus. We undertake no obligation to revise or publicly release the results of any revision to these
  forward-looking statements, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking
  events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from
  those anticipated or implied in the forward-looking statement. You should not place undue reliance on any forward-looking statement,
  each of which applies only as of the date of this prospectus. You are advised, however, to consult any further disclosures we make
  on related subjects in our reports on Forms 10-K, 10-Q and 8-K filed with the Commission after the date of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">ii</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights selected information
  contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in
  our Company. You should carefully read the entire prospectus, including all documents incorporated by reference herein. In particular,
  attention should be directed to our &ldquo;Risk Factors,&rdquo; &ldquo;Information with Respect to the Company,&rdquo; &ldquo;Management&rsquo;s
  Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the financial statements and related notes thereto
  contained herein or otherwise incorporated by reference hereto, before making an investment decision.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>All references to &ldquo;we,&rdquo; &ldquo;us,&rdquo;
  &ldquo;our,&rdquo; and the &ldquo;Company&rdquo; mean Relmada Therapeutics, Inc. and its subsidiary Relmada Therapeutics, Inc. (Delaware).</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Relmada Therapeutics,
  Inc. (Relmada or the Company, we or us) (a Nevada corporation), is a clinical-stage biotechnology company focused on the development
  of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone an isomer of
  methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous
  system (CNS) diseases and other disorders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our lead product candidate,
  esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. On October
  15, 2019, we reported top-line data from study REL-1017-202. This was a double-blind, placebo-controlled Phase 2 clinical trial evaluating
  the safety, tolerability and efficacy of two oral doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment
  in patients with major depressive disorder (MDD), who experienced an inadequate response to 1 to 3 adequate antidepressant treatments
  with an antidepressant medication.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Phase 2 Clinical
  Trial</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the REL-1017-202
  study, 62 subjects, with an average age of 49.2 years, with an average Hamilton Depression Rating Scale score of 25.3 and an average
  Montgomery-Asberg Depression Rating Scale (MADRS) score of 34.0 (severe depression), were randomized. Other demographic characteristics
  were balanced across all arms. After an initial screening period, subjects were randomized to one of three arms: placebo, REL-1017 25
  mg or REL-1017 50 mg, in addition to stable background antidepressant therapy. Subjects in the REL-1017 treatment arms received one loading
  dose of either 75 mg (25 mg arm) or 100 mg (50 mg arm) of REL-1017. Subjects were treated inpatient for 7 days and discharged home at
  Day 9. They returned for follow-up visits at Day 14 and Day 21. Efficacy was measured on Days 2, 4 and 7 in the dosing period and on
  Day 14, one week after treatment discontinuation. 61 subjects received all treatment doses and were included in the per-protocol population
  (PPP) treatment analysis; 57 subjects completed all visits. All 62 randomized subjects were part of the intention-to-treat (ITT) analysis.
  No differences were observed between the ITT and PPP analyses and results.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We observed that subjects
  in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement on all efficacy measures tested
  as compared to subjects in the placebo group, including: MADRS; the Clinical Global Impression &ndash; Severity (CGI-S) scale; the Clinical
  Global Impression &ndash; Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Improvements on the
  MADRS endpoint appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation,
  with P values&lt; 0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0.
  Similar findings emerged from the CGI-S and CGI-I scales.&nbsp;<B>&nbsp;&nbsp;</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The study also confirmed
  the tolerability profile of REL-1017, which was observed in the Phase 1 studies. Subjects experienced only mild and moderate adverse
  events (AEs), and no serious adverse events, without significant differences between placebo and treatment groups. The AEs observed in
  the Phase 2a clinical study were of the same nature as those observed in the Phase 1 clinical studies of d-Methadone, and there was no
  evidence of either treatment induced psychotomimetic and dissociative AEs or withdrawal signs and symptoms upon treatment discontinuation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Phase 3 Program</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 20, 2020,
  Relmada announced that the first patient had been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company&rsquo;s lead
  product candidate, REL-1017, as an adjunctive treatment for MDD.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 1, 2021, Relmada
  announced the initiation of RELIANCE II, the second of two sister pivotal Phase 3 clinical trials (RELIANCE I and RELIANCE II) for the
  Company&rsquo;s lead product candidate, REL-1017, as an adjunctive treatment for MDD.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 4, 2021,
  Relmada announced the initiation of RELIANCE III study, a monotherapy trial for the Company&rsquo;s lead product candidate, REL-1017.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 9, 2022, Relmada
  announced that the FDA granted Fast Track designation to REL-1017 as a monotherapy for the treatment of MDD.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 13, 2022,
  Relmada announced that its RELIANCE III study, evaluating REL-1017 in the monotherapy setting for MDD, did not achieve its primary endpoint,
  which was a statistically significant improvement in depression symptoms compared to placebo as measured by MADRS on Day 28. In the study,
  the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected
  placebo response.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 7, 2022,
  Relmada announced that its RELIANCE I study, evaluating REL-1017 as an adjunctive treatment for MDD, did not achieve its primary endpoint,
  which was a statistically significant improvement in depression symptoms compared to placebo as measured by MADRS on Day 28. In the study,
  the REL-1017 treatment arm (n= 113) showed a MADRS reduction of 15.1 points at Day 28 versus 12.9 points for the placebo arm (n=114),
  which is a clinically meaningful difference of 2.2 points on the MADRS. The study also showed a nominally statistically significant difference
  in the response rate, with a response rate of 39.8% in the REL-1017 arm vs 27.2% in the placebo arm (p&lt;0.05).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Patients who complete
  the RELIANCE trials are eligible to rollover into the long-term, open-label study, which also is expected to include subjects who had
  not previously participated in a REL-1017 clinical trial.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, in order
  to support potential regulatory submissions seeking approval for REL-1017 as monotherapy and adjunctive treatment, the FDA confirmed
  that, based on what is known at this time, Relmada will not be required to conduct a two-year carcinogenicity study of REL-1017, as sufficient
  clinical data have been generated to date. The FDA also confirmed that Relmada does not need to conduct a Thorough QT analysis (TQT)
  cardiac study in humans to support cardiac safety in potential regulatory submissions for REL-1017, as the data provided so far and the
  data generated by the Phase 3 program will be adequate to evaluate the cardiac safety profile of REL-1017.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Human Abuse Potential (HAP) Studies</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Top-line Results - Oxycodone:</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 27, 2021, Relmada
  announced top-line results that showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg, the therapeutic, supratherapeutic and
  maximum tolerated doses (MTD), respectively, tested in recreational opioid users, demonstrated a highly statistically significant difference
  vs. the active control drug, oxycodone 40 mg. The study&rsquo;s primary endpoint was a measure of &ldquo;likability&rdquo; with the subjects
  rating the maximum effect (or Emax) for Drug Liking &ldquo;at the moment&rdquo;, using a 1-100 bipolar rating scale (known as a visual
  analog scale or VAS), with 100 as the highest likability, 50 as neutral (placebo-like), and 0 the highest dislike. In summary, all tested
  doses of REL-1017, including the 150 mg MTD, showed a highly statistically significant difference in abuse potential versus oxycodone
  with p-values less than 0.05. Consistent results were seen for the secondary endpoints. Additionally, all REL-1017 doses including 150
  mg (6 times the therapeutic dose and MTD) were statistically equivalent to placebo (p&lt;0.05). These results support the lack of opioid
  effects of REL-1017.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Top-line Results - Ketamine:</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On February 23, 2022,
  Relmada announced top-line results that showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg, the therapeutic, supratherapeutic
  and MTD, respectively) tested in recreational drug users, demonstrated a substantial (30+ points) and statistically significant difference
  vs. the active control drug, intravenous ketamine 0.5 mg/kg over 40 minutes, and, importantly, were statistically equivalent to placebo.
  The study&rsquo;s primary endpoint was a measure of &ldquo;likability&rdquo; with the subjects rating the maximum effect (or Emax) for
  Drug Liking &ldquo;at this moment&rdquo;, using a 1-100 bipolar rating scale (known as a visual analog scale or VAS), with 100 as the
  highest likability, 50 as neutral (placebo-like), and 0 the highest dislike. Consistent results are seen for the secondary endpoints.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Key Upcoming Anticipated Milestones</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We expect multiple key
  milestones over the next 12-18 months. These include:&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results of RELIANCE II,
      the second of two adjunctive MDD trials, in the first half of 2024.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of a new Phase
      III adjunctive MDD trial in mid-2023 with completion anticipated in the second half of 2024. &nbsp;</FONT></TD></TR>
  
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results of
      RELIANCE &ndash; OLS (Long-term, Open-label) study in MDD in mid-2023.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Development Program</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Esmethadone (d-Methadone,
  dextromethadone, REL-1017) as a treatment for MDD</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Background</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In 2020, the National
  Institute of Mental Health (NIMH) estimated that 21.0 million adults aged 18 or older in the United States had at least one major depressive
  episode in the past year. According to data from nationally representative surveys supported by NIMH, only about half of Americans diagnosed
  with major depression in a given year receive treatment. Of those receiving treatment with as many as four different standard antidepressants,
  33% of drug-treated depression patients do not achieve adequate therapeutic benefits according to the Sequenced Treatment Alternatives
  to Relieve Depression (STAR*D) trial published in the American Journal of Psychiatry.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
  addition to the high failure rate, only two of the marketed products for depression, esketamine (marketed by Johnson and Johnson as Spravato&reg;),
  an in-clinic nasal spray treatment, and dextromethorphan-bupropion (marketed by Axsome as Auvelity</FONT><FONT STYLE="font-family: Symbol">&auml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">),
  can demonstrate rapid antidepressant effects, while the other currently approved products can take two to eight weeks to show activity.
  The urgent need for improved, faster acting antidepressant treatments is underscored by the fact that severe depression can be life-threatening,
  due to heightened risk of suicide.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Esmethadone Overview
  and Mechanism of Action</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Esmethadone&rsquo;s
  mechanism of action, as a low affinity, non-competitive NMDA channel blocker or antagonist, is fundamentally differentiated from most
  currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively with standard, FDA-approved antidepressants.
  Working through the same brain mechanisms as ketamine and esketamine but potentially lacking their adverse side effects, esmethadone
  is being developed as a rapidly acting, oral agent for the treatment of depression and potentially other CNS conditions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In chemistry an enantiomer,
  also known as an optical isomer, is one of two stereoisomers that are mirror images of each other that are non-superimposable (not identical),
  much as one&rsquo;s left and right hands are the same except for being reversed along one axis. A racemic compound, or racemate, is one
  that has equal amounts of left- and right-handed enantiomers of a chiral molecule. For racemic drugs, often only one of a drug&rsquo;s
  enantiomers is responsible for the desired physiologic effects, while the other enantiomer is less active or inactive.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a single isomer of
  racemic methadone, esmethadone has been shown to possess NMDA antagonist properties with virtually no traditional opioid or ketamine-like
  adverse events at the expected therapeutic doses. In contrast, racemic methadone is associated with common opioid side effects that include
  anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhea, drowsiness, and others. It has
  been shown that the left (levo) isomer, l-methadone, is largely responsible for methadone&rsquo;s opioid activity, while the right (dextro)
  isomer, esmethadone, at the currently therapeutic doses used in development is virtually inactive as an opioid while maintaining affinity
  for the NMDA receptor.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">NMDA receptors are present
  in many parts of the CNS and play important roles in regulating neuronal activity and promoting synaptic plasticity in brain areas important
  for cognitive functions such as executive function, learning and memory. Based on these premises, esmethadone could show benefits in
  several different CNS indications.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Esmethadone (d-methadone,
  dextromethadone, REL-1017) in other indications</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While our current strategy
  is currently to focus on the further development of esmethadone as an adjunctive treatment of MDD, we may in the future re-commence testing
  of esmethadone as a monotherapy for MDD. In addition, we are evaluating other indications that Relmada may explore in the future, including
  restless leg syndrome and other glutamatergic system activation related diseases.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About This Offering</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the public offering,
  which is not being underwritten, by the Selling Stockholders listed in this prospectus, of up to 6,020,608 shares of our Common Stock.
  Of the shares being offered, 6,020,608 of which are currently issued and outstanding. The shares offered by this prospectus may be sold
  by the Selling Stockholders from time to time in the open market, through negotiated transactions or otherwise at market prices prevailing
  at the time of sale or at negotiated prices. We will receive none of the proceeds from the sale of the shares by the Selling Stockholders.
  We will bear all expenses of registration incurred in connection with this offering, but all selling and other expenses incurred by the
  Selling Stockholders will be borne by them.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Listing</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Stock is listed on The Nasdaq Global
  Select Market under the symbol &ldquo;RLMD.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
  at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134 and our telephone number is +1-646-876-3459. Our website address
  is&nbsp;<I>www.relmada.com</I>. The information contained therein or connected thereto shall not be deemed to be incorporated into
  this prospectus or the registration statement of which it forms a part. The information on our website is not part of this
  prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high degree
  of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described under
  the caption &ldquo;Risk Factors&rdquo; and elsewhere in our most recent Annual Report on Form 10-K, , quarterly reports on Form 10-Q
  and current reports on Form 8-K that we have filed or will file with the SEC, which are incorporated by reference into this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business, affairs, prospects, assets, financial
  condition, results of operations and cash flows could be materially and adversely affected by these risks. For more information about
  our SEC filings, please see &ldquo;Where You Can Find More Information.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares which may be sold under this reoffer
  prospectus will be sold for the respective accounts of each of the Selling Stockholders listed herein (which includes our executive officers
  and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our Common Stock. We will receive proceeds
  from the exercise of the options; however, no assurance can be given as to when or if any or all of the options will be exercised. If
  any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate purposes. All expenses
  of the registration of the shares will be paid by us. See &ldquo;Selling Stockholders&rdquo; and &ldquo;Plan of Distribution.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SELLING STOCKHOLDERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus relates to shares of
  Common Stock that are being registered for reoffer and resale by Selling Stockholders who have received or acquired, or may hereafter
  receive or acquire, the shares pursuant to the Plans. The Selling Stockholders may resell all, a portion, or none of the shares of Common
  Stock from time to time.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth (a) the name
  of each Selling Stockholder; (b) the number of shares of Common Stock beneficially owned by each Selling Stockholder as of June 12,
  2023; (c) the maximum number of shares of Common Stock that each Selling Stockholder may offer for sale from time to time pursuant
  to this reoffer prospectus, whether or not the Selling Stockholder has any present intention to do so and whether or not such shares
  have previously been issued to the Selling Stockholders or may be issued in the future if at all; and (d) the number of shares of
  Common Stock and the percentage of the Company&rsquo;s outstanding Common Stock that would be beneficially owned by each Selling
  Stockholder assuming the sale of all of that Selling Stockholder&rsquo;s shares offered hereby. The percentage of our outstanding
  Common Stock to be owned by each Selling Stockholder assuming the sale of all of that Selling Stockholder&rsquo;s shares offered
  hereby is based on 30,099,203 shares of Common Stock issued and outstanding as of June 12, 2023. All information with respect to
  beneficial ownership has been furnished by the Selling Stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
  with the rules of the Commission and generally includes voting or investment power with respect to securities. Options to purchase and
  rights to receive shares of Common Stock that are currently exercisable or vested, or which are exercisable or vest within 60 days of
  the date of this prospectus are deemed to be outstanding and to be beneficially owned by the person holding such options for the purpose
  of computing the percentage ownership of any other person. Shares of restricted stock, whether vested or unvested, are deemed to be outstanding
  and to be beneficially owned by the person holding such restricted stock for the purpose of computing the percentage ownership of such
  person and are treated as outstanding for the purpose of computing the percentage ownership of each other person.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information concerning the identities of the
  Selling Stockholders, the number of shares that may be sold by each Selling Stockholder and information about the shares beneficially
  owned by the Selling Stockholders may from time to time be updated in supplements to this reoffer prospectus, which will be filed with
  the SEC in accordance with Rule 424(b) of the Securities Act if and when necessary. The names of persons selling shares under this reoffer
  prospectus and the amount of such shares are set forth below to the extent we presently have such information. However, other affiliate
  Selling Stockholders may elect to sell shares pursuant to this reoffer prospectus as they receive them from time to time.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The address of each Selling Stockholder is c/o
  Relmada Therapeutics, Inc., 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, Florida 33134.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Number of Shares Beneficially<BR>
      Owned Prior to Offering (1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of<BR>
      Shares Being</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Number of Shares Beneficially<BR>
      Owned After Offering (1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent (%)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Offered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent (%)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 40%; text-align: left">Sergio Traversa</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,795,114</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.7</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,994,722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">144,024</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Maged Shenouda</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,035,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Charles Ence</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">494,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,040,597</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Cedric O&rsquo;Gorman</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Charles Casamento</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449,551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Paul Kelly</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">796,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Eric Schmidt</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">412,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">John Glasspool</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">Fabiana Fedeli</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 4pt">Totals</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,216,743</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17.3</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,020,608</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">443,668</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double"><B>*</B></FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
                                              than 1%</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              securities &ldquo;beneficially owned&rdquo; by a person are determined in accordance with
                                              the definition of &ldquo;beneficial ownership&rdquo; set forth in the rules and regulations
                                              promulgated under the Exchange Act, and accordingly, may include securities owned by and
                                              for, among others, the spouse and/or minor children of an individual and any other relative
                                              who has the same home as such individual, as well as other securities as to which the individual
                                              has or shares voting or investment power or which such person has the right to acquire within
                                              60 days of June 12, 2023 pursuant to the exercise of options, or otherwise. Beneficial ownership
                                              may be disclaimed as to certain of the securities.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of Common Stock covered by this reoffer
  prospectus are being registered by the Company for the account of the Selling Stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of Common Stock offered may be sold
  from time to time directly by or on behalf of each Selling Stockholder in one or more transactions on the Nasdaq Global Select Market
  or any other stock exchange on which the Common Stock may be listed at the time of sale, in privately negotiated transactions, or through
  a combination of such methods, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at
  fixed prices (which may be changed) or at negotiated prices. The Selling Stockholders may sell shares through one or more agents, brokers
  or dealers or directly to purchasers. Such brokers or dealers may receive compensation in the form of commissions, discounts or concessions
  from the Selling Stockholders and/or purchasers of the shares or both. Such compensation as to a particular broker or dealer may be in
  excess of customary commissions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may use any one or more
  of the following methods when disposing of Common Stock or interests therein:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                              brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                              trades in which the broker-dealer will attempt to sell the Common Stock as agent, but may
                                              position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
                                              by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                              exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
                                              negotiated transactions;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short
                                              sales effected after the date the registration statement of which this reoffer prospectus
                                              is a part is declared effective by the SEC;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                              the writing or settlement of options or other hedging transactions, whether through an options
                                              exchange or otherwise;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers
                                              may agree with the Selling Stockholders to sell a specified number of such Common Stock at
                                              a stipulated price per share;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                              combination of any such methods of sale; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                              other method permitted by applicable law.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may, from time to time,
  pledge or grant a security interest in some or all of the Common Stock owned by them and, if they default in the performance of their
  secured obligations, the pledgees or secured parties may offer and sell the common stock, from time to time, under this reoffer prospectus,
  or under an amendment to this reoffer prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the
  list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this reoffer
  prospectus. The Selling Stockholders also may transfer the Common Stock in other circumstances, in which case the transferees, pledgees
  or other successors in interest will be the selling beneficial owners for purposes of this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of our Common Stock
  or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
  which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The Selling Stockholders
  may also sell our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock
  to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
  broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such
  broker-dealer or other financial institution of Common Stock offered by this reoffer prospectus, which shares such broker-dealer or other
  financial institution may resell pursuant to this reoffer prospectus (as supplemented or amended to reflect such transaction).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with their sales, a Selling Stockholder
  and any participating broker or dealer may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, and any
  commissions they receive and the proceeds of any sale of shares may be deemed to be underwriting discounts and commissions under the
  Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are bearing all costs relating to the registration
  of the shares of Common Stock. Any commissions or other fees payable to brokers or dealers in connection with any sale of the shares
  will be borne by the Selling Stockholders or other party selling such shares. Sales of the shares must be made by the Selling Stockholders
  in compliance with all applicable state and federal securities laws and regulations, including the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to any shares sold hereunder, Selling
  Stockholders may sell shares of Common Stock in compliance with Rule 144. There is no assurance that the Selling Stockholders will sell
  all or a portion of the Common Stock offered hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may agree to indemnify
  any broker, dealer or agent that participates in transactions involving sales of the shares against certain liabilities in connection
  with the offering of the shares arising under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have notified the Selling Stockholders of
  the need to deliver a copy of this reoffer prospectus in connection with any sale of the shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters relating to the validity
  of the issuance of Common Stock in this offering are being passed upon for us by Sichenzia Ross Ference LLP, New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>EXPERTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements incorporated by reference
  into this prospectus have been so included in reliance on the report of Marcum LLP, an independent registered public accounting firm,
  related to the consolidated financial statements as of December 31, 2022 and 2021, and each of the two years in the period
  ended December 31, 2022, given on the authority of said firm as experts
  in auditing and accounting.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 16; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporating by reference certain information
  that we have filed with the Commission under the informational requirements of the Exchange Act, which means that we disclose important
  information to you by referring to another document filed separately with the Company. The information contained in the documents we
  are incorporating by reference is considered to be a part of this reoffer prospectus, and the information that we later file with the
  SEC will automatically update and supersede the information contained or incorporated by reference in this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents filed with the SEC are
  incorporated by reference in this reoffer prospectus:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023022463/f10k2022_relmadatherap.htm">Form 10-K</A>&nbsp;for the fiscal year ended December 31, 2022, filed with the Commission on March 23, 2023;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Quarterly Report on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023038533/f10q0323_relmadatherap.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A>&nbsp;for the quarterly period ended March 31, 2023, filed
                                              with the Commission on May 11, 2023;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Current Reports on Form 8-K filed with the Commission on&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023001162/ea171314-8k_relmada.htm">January 5, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023002865/ea171670-8k_relmada.htm">January 17, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023030851/ea177149-8k_relmada.htm">April 19, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023040004/ea178627-8k_relmada.htm" STYLE="-sec-extract: exhibit">May 15, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023043101/ea179287-8k_relmada.htm">May 25, 2023</A>;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Definitive Proxy Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390023025007/def14a0323_relmada.htm">Schedule 14A</A>&nbsp;filed with the Commission on March 31,
                                              2023; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              description of certain capital stock contained in our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1553643/000121390019019910/f8a12b100719_relmadathera.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>
                                              filed on October 8, 2019, as it may further be amended from time to time.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All documents filed with the Commission by us
  pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this reoffer prospectus and prior to the
  termination of the offering relating to this reoffer prospectus (other than such portions and exhibits of the respective filings that
  were furnished pursuant to Items 2.02 or 7.01 of Current Reports on Form 8-K and not deemed filed under the Exchange Act) will be deemed
  to be incorporated by reference into this reoffer prospectus and to be a part of this reoffer prospectus from the date of filing of those
  documents. Any statement incorporated or deemed to be incorporated by reference into this reoffer prospectus will be deemed to be modified,
  replaced or superseded for purposes of this reoffer prospectus to the extent that a statement contained in this Reoffer Prospectus or
  in any other subsequently filed document, that also is or is deemed to be incorporated by reference into this reoffer prospectus modifies,
  replaces or supersedes that statement. Any statement so modified, replaced or superseded will be deemed, except as so modified, replaced
  or superseded, to constitute a part of this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus refers to certain documents
  that are not presented herein or delivered herewith. Such documents are available to any person, including any beneficial owner of our
  shares, to whom this reoffer prospectus is delivered upon oral or written request, without charge. Requests for such documents should
  be directed to Investor Relations, Relmada Therapeutics, Inc., 2222 Ponce de Leon Blvd, Floor&nbsp;3, Coral Gables, Florida 33134. Please
  note that additional information can be obtained from our website at&nbsp;<I>www.relmada.com</I>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual and special reports and other information
  with the SEC.&nbsp;Certain of our SEC filings are available over the Internet at the SEC&rsquo;s web site at&nbsp;<I>http://www.sec.gov</I>.
  You may also read and copy any document we file with the SEC at its public reference facilities:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Public Reference Room Office 100 F Street, N.E.<BR>
  Room 1580<BR>
  Washington, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also obtain copies of the documents at
  prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Callers
  in the United&nbsp;States can also call (202)&nbsp;551-8090&nbsp;for further information on the operations of the public reference facilities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;3.</B>&nbsp;<B>Incorporation of
  Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents filed by the Registrant
  with the Commission are incorporated herein by reference (excluding any portions of such documents that have been &ldquo;furnished&rdquo;
  but not &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)):</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
      <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023022463/f10k2022_relmadatherap.htm">Form 10-K</A>&nbsp;for the fiscal year ended December 31, 2022, filed with the Commission on March 23, 2023;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Quarterly Report on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023038533/f10q0323_relmadatherap.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A>&nbsp;for the quarterly period ended March 31, 2023, filed
                                              with the Commission on May 11, 2023;</FONT></TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Current Reports on Form 8-K filed with the Commission on&nbsp;<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023001162/ea171314-8k_relmada.htm">January 5, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023002865/ea171670-8k_relmada.htm">January 17, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023030851/ea177149-8k_relmada.htm">April 19, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023040004/ea178627-8k_relmada.htm" STYLE="-sec-extract: exhibit">May 15, 2023</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1553643/000121390023043101/ea179287-8k_relmada.htm">May 25, 2023</A>;</FONT></TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                              Definitive Proxy Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390023025007/def14a0323_relmada.htm">Schedule 14A</A>&nbsp;filed with the Commission on March 31,
                                              2023; and</FONT></TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              description of certain capital stock contained in our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1553643/000121390019019910/f8a12b100719_relmadathera.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>
                                              filed on October 8, 2019, as it may further be amended from time to time.</FONT></TD>
  </TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, all documents subsequently filed
  by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of the post-effective amendment
  to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining
  unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing
  of such documents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statement contained in a document incorporated
  or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement
  to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to
  be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be
  deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under no circumstances will any information filed
  under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the
  contrary.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may request a copy of these filings, at no
  cost, by writing or telephoning the Registrant at:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">880 Third Avenue</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2222 Ponce de Leon Blvd.,&nbsp;Floor 3</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Coral Gables,&nbsp;FL 33134</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: 212-547-9591</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Investor Relations</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information provided
  or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide
  you with different information. You should not assume that the information in this Registration Statement or any related prospectus is
  accurate as of any date other than the date on the front of the document.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;5. Interests of Named Experts and
  Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;6. Indemnification of Directors
  and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant is a Nevada corporation and generally
  governed by the Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes, or NRS.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.138 of the NRS provides that, unless
  the corporation&rsquo;s Articles of Incorporation provide otherwise, a director or officer will not be individually liable unless it
  is proven that (i) the director&rsquo;s or officer&rsquo;s acts or omissions constituted a breach of his or her fiduciary duties, and
  (ii) such breach involved intentional misconduct, fraud, or a knowing violation of the law. Our Articles of Incorporation provide that
  no director or officer shall be personally liable to the corporation or any of its stockholders for damages for any breach of fiduciary
  duty as a director or officer except for liability of a director or officer for (i) acts or omissions involving intentional misconduct,
  fraud, or a knowing violation of law or (ii) payment of dividends in violation of Section 78-300 of the NRS.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.7502 of the NRS permits a company
  to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred
  in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i) is not liable pursuant
  to NRS 78.138, or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the
  best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer
  or director was unlawful. Section 78.7502 of the NRS also precludes indemnification by the corporation if the officer or director has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable to the corporation or for amounts paid
  in settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the
  person is fairly and reasonably entitled to indemnity for such expenses and requires a corporation to indemnify its officers and directors
  if they have been successful on the merits or otherwise in defense of any claim, issue, or matter resulting from their service as a director
  or officer.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.751 of the NRS permits a Nevada company
  to indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding
  as they are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board members,
  or by independent legal counsel. Section 78.751 of NRS requires a corporation to advance expenses as incurred upon receipt of an undertaking
  by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that
  such officer or director is not entitled to be indemnified by the company if so provided in the corporations articles of incorporation,
  bylaws, or other agreement. Section 78.751 of the NRS further permits the company to grant its directors and officers additional rights
  of indemnification under its articles of incorporation, bylaws, or other agreement.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Exhibits to this Registration Statement are
  listed in the Exhibit Index to this Registration Statement, which Exhibit Index is incorporated herein by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The undersigned Registrant hereby undertakes:</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being
  made, a post-effective amendment to the Registration Statement:</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">to include any prospectus required by Section&nbsp;10(a)(3)
  of the Securities Act;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">to reflect in the prospectus any facts or events arising
  after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in
  the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing,
  any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
  was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
  filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change
  in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective Registration
  Statement; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">to include any material information with respect to the plan
  of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration
  Statement.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>provided, however</I>, that paragraphs
  (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a
  post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant
  to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under
  the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
  offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective
  amendment any of the securities being registered which remain unsold at the termination of the offering.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The undersigned Registrant hereby undertakes that, for purposes
  of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual report pursuant to Section&nbsp;13(a)
  or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant
  to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the
  Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
  or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as
  expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
  with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
  expressed in the Securities Act and will be governed by the final adjudication of such issue.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 20; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
  S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
  City of New York, State of New York, on this 21st day of June, 2023&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relmada Therapeutics, Inc.</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sergio
      Traversa&#8239;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sergio Traversa</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and (Duly Authorized Officer
      and Principal Executive Officer)</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Maged
      Shenouda</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maged Shenouda</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the undersigned directors and officers
  of Relmada Therapeutics, Inc., a Nevada corporation, do hereby constitute and appoint Sergio Traversa the undersigned&rsquo;s true and
  lawful attorney and agent, with full power of substitution and resubstitution in each, to do any and all acts and things in our name
  and on our behalf in our respective capacities as directors and officers and to execute any and all instruments for us and in our names
  in the capacities indicated below, which said attorneys and agents, or either one of them, may deem necessary or advisable to enable
  said corporation to comply with the Securities Act, as amended, and any rules, regulations and requirements of the Securities and Exchange
  Commission, in connection with this registration statement, including specifically, but without limitation, power and authority to sign
  for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto,
  and each of the undersigned does hereby ratify and confirm all that said attorneys and agents, or either one of them or any substitute,
  shall do or cause to be done by virtue hereof. This Power of Attorney may be executed in any number of counterparts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Charles Ence</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Accounting and Compliance Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Ence</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Accounting Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Charles Casamento</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chairman of the Board</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Casamento</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Kelly</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Kelly</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Glasspool</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Glasspool</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eric Schmidt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Schmidt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fabiana Fedeli</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fabiana Fedeli</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 21; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
      No.</B></FONT></TD>
      <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000125529412000776/ex3_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 filed with the SEC on November 13, 2012).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000125529414000454/ex4_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Report on Form 8-K filed with the SEC on May 19, 2014).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390014003891/f8k053014ex3i_campnine.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Certificate of Amendment to Articles of Incorporation, effective May 30, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on June 2, 2014).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390014004859/f8k070814ex3i_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Certificate of Amendment to Articles of Incorporation, effective July 8, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on July 14, 2014).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390015001037/f10q1214ex3i_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Certificate of Amendment to Articles of Incorporation, effective February 12, 2015 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed with the SEC on February 13, 2015).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390015005856/f8k080415ex3i_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Certificate of Change Pursuant to NRS 78,209, effective August 11, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on August 10, 2015).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390015009111/f8k112015ex3ii_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 of Relmada&rsquo;s Form 8-K filed with the SEC on November 25, 2015).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390019008633/f10q0319ex3-1_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation, dated April 12, 2019 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on May 14, 2019).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390019019122/f8k092719aex3-1_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Certificate of Change Pursuant to NRS 78.209, effective September 26, 2019 (incorporated by reference to Exhibit 3.1 of Relmada&rsquo;s Form 8-K filed with the SEC on September 27, 2019).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390022058066/ea166170ex3-1_relmadather.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation, dated September 22, 2022 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on September 22, 2022).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390015007443/fs82015ex4i_relmadatherape.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 2, 2015).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea180431ex5-1_relmadatherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sichenzia Ross Ference LLP*</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea180431ex23-1_relmadatherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP*</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea180431ex5-1_relmadatherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1)*</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)*</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390021028217/ea141456ex10-1_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relmada Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 20, 2021).</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/ea179287ex10-1_relmada.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relmada Therapeutics, Inc. 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 25, 2023).</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea180431ex-fee_relmadatherap.htm">Filing Fee Table</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                              herewith</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-5</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea180431-s8_relmadatherap.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 170966}]
metadata_filer: {"company-data": {"conformed-name": "RELMADA THERAPEUTICS, INC.", "cik": "0001553643", "assigned-sic": "2834", "irs-number": "455401931", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-272811", "film-number": "231030639"}, "business-address": {"street1": "2222 PONCE DE LEON BLVD. 3RD FLOOR", "city": "CORAL GABLES", "state": "FL", "zip": "33134", "phone": "646 876 3459"}, "mail-address": {"street1": "2222 PONCE DE LEON BLVD. 3RD FLOOR", "city": "CORAL GABLES", "state": "FL", "zip": "33134"}, "former-company": {"former-conformed-name": "CAMP NINE, INC.", "date-changed": "20120706"}}
text: As filed with the Securities and Exchange Commission
  on June 21, 2023
  Registration No. 333-
  Registration No. 333-257723
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, DC 20549
  FORM S-8
  REGISTRATION STATEMENT
  AND POST-EFFECTIVE AMENDMENT NO. 1 TO:
  FORM S-8 REGISTRATION STATEMENT NO. 333-257723
  UNDER
  THE SECURITIES ACT OF 1933
  RELMADA THERAPEUTICS, INC.
  (Exact Name of Registrant as Specified in Its
  Charter)
  Nevada
  45-5401931
  (State
      or other Jurisdiction of
  (I.R.S
      Employer
  Incorporation
      or Organization)
  Identification
      Number)
  2222 Ponce de Leon Blvd., Floor 3
  Coral Gables, FL
  33134
  (Address
      of Principal Executive Offices)
  (Zip
      Code)
  RELMADA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE
  PLAN
  (Full Title of the Plans)
  Sergio Traversa
  Chief Executive Officer
  2222 Ponce de Leon Blvd., Floor 3
  Coral Gables, FL
  Phone: (212) 547-9591
  (Name, Address and Telephone Number of Agent for Service)
  Copy to:
  Gregory Sichenzia, Esq.
  Barrett DiPaolo, Esq.
  Sichenzia Ross Ference LLP
  1185 Avenue of the Americas
  New York, New York 10036
  +1-212-930-9700
  Indicate by check mark whether
  the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging
  growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting
  company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large
      accelerated filer
  ☐
  Accelerated
      filer
  ☐
  Non-accelerated
      filer
  ☒
  Smaller
      reporting company
  ☒
  Emerging
      Growth Company
  ☐
  If an emerging growth company,
  indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
  financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  EXPLANATORY NOTE
  This Registration Statement on Form S-8 is being
  filed by Relmada Therapeutics, Inc. (the "Company"), pursuant to General Instruction E to the Form S-8 Registration Statement
  under the Securities Act of 1933, as amended, to register an additional 6,400,000 shares of the Company's common stock, par
  value $0.001 per share (the "Common Stock") issued or issuable pursuant to awards under the Company's 2021 Equity Incentive
  Plan, as amended (the "2021 Plan);
  1,500,000 shares of Common Stock issued or issuable
  under the 2021 Plan have been previously registered pursuant to the Company's Registration Statement on Form S-8 (File No. 333-257723),
  filed with the Securities and Exchange on July 6, 2021, and the information contained therein is incorporated herein by reference.
  This Registration also includes a reoffer prospectus
  pursuant to Form S-3 (in accordance with Section C of the General Instructions to the Form S-8), which covers reoffers and resales of
  "restricted securities" and/or "control securities" (as such terms are defined in Section C of the General
  Instructions to Form S-8). This reoffer prospectus relates to offers and resales by directors and executive officers of shares of Common
  Stock and shares of Common Stock that are issuable upon the exercise of awards granted by the Company pursuant to the 2021 Plan. This
  reoffer prospectus may be used by the Selling Stockholders holders for reoffers and resales on a continuous or delayed basis in the future
  shares of Common Stock issued pursuant to the 2021 Plan.
  The second part of this Registration Statement
  contains information required in the Registration Statement pursuant to Part II of Form S-8.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1.
  Plan Information
  The documents containing the information
  specified in Part I of Form S-8 will be sent or given to each recipient of a grant under the 2021 Plan (the "Recipient")
  in accordance with Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and
  Exchange Commission (the "Commission" or the "SEC") and the instructions to Form S-8, such documents are not
  being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant
  to Rule 424 under the Securities Act. Such documents and the documents incorporated by reference into this Registration
  Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the
  requirements of Section 10(a) of the Securities Act.
  Item 2. Registrant Information and Employee
  Plan Annual Information.
  We will provide to each Recipient a written statement
  advising of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents
  are incorporated by reference in this Section 10(a) prospectus) and of documents required to be delivered pursuant to Rule 428(b) under
  the Securities Act without charge and upon written or oral request by contacting:
  Relmada Therapeutics, Inc.
  2222 Ponce de Leon Blvd., Floor 3
  Coral Gables, FL 33134
  Telephone: 212-547-9591
  Attn: Investor Relations
  REOFFER PROSPECTUS
  6,020,608 Shares
  Common Stock
  Issued or issuable under certain awards
  granted under the 2021 Plan
  This reoffer prospectus relates to 6,020,608
  shares of our common stock, $0.001 par value per share (the "Common Stock") that may be reoffered or resold, from time to
  time, by certain stockholders identified herein in the section entitled "Selling Stockholders." Such shares have been or
  may be acquired in connection with awards granted under the Relmada Therapeutics, Inc. (the "Company") 2021 Equity Incentive
  Plan (as amended, the "2021 Plan").
  The Selling Stockholders, or their pledgees,
  donees, transferees or other successors-in-interest, may offer and sell their shares on the Nasdaq Global Select Market, or such other
  stock market or exchange on which our Common Stock may be listed or quoted, in negotiated transactions or otherwise, at market prices
  prevailing at the time of the sale, at prices related to prevailing market prices or at prices otherwise negotiated (see "Plan
  of Distribution" starting on page 9 of this prospectus). We will receive no part of the proceeds from sales made under this reoffer
  prospectus. The Selling Stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection
  with the registration and offering and not borne by the Selling Stockholders will be borne by us.
  This reoffer prospectus has been prepared for
  the purposes of registering the shares under the Securities Act to allow for future sales by Selling Stockholders on a continuous or
  delayed basis to the public without restriction. We have not entered into any underwriting arrangements in connection with the sale of
  the shares covered by this reoffer prospectus.
  Investing in our securities involves certain
  risks. See "Risk Factors" beginning on page 5 and the risk factors in our most recent Annual Report on Form 10-K, which are
  incorporated by reference herein, as well as in any other more recently filed annual, quarterly or current reports and, if any, in the
  relevant prospectus supplement. We urge you to carefully read this prospectus and the accompanying prospectus supplement, together with
  the documents we incorporate by reference, describing the terms of these securities before investing.
  Our Common Stock is quoted on the Nasdaq Global Select
  Market under the symbol "RLMD." The last reported sale price of our Common Stock on the Nasdaq Global Select Market on June
  16, 2023, was $2.60 per share.
  Neither the Securities and Exchange Commission
  nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
  Any representation to the contrary is a criminal offense.
  The date of this reoffer prospectus is June 21, 2023
  TABLE OF CONTENTS
  Page
  Cautionary
      Statement Regarding Forward-Looking Statements
  ii
  Prospectus
      Summary
  1
  Risk
      Factors
  5
  Use
      of Proceeds
  6
  Selling
      Stockholders
  7
  Plan
      of Distribution
  9
  Legal
      Matters
  10
  Experts
  10
  Incorporation
      of Certain Documents by Reference
  11
  Where
      You can Find Additional Information
  11
  i
  CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
  This prospectus and any accompanying prospectus
  supplement and the documents incorporated by reference herein may contain forward looking statements that involve risks and uncertainties.
  All statements other than statements of historical fact contained in this prospectus and any accompanying prospectus supplement and the
  documents incorporated by reference herein, including statements regarding future events, our future financial performance, business
  strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify
  forward-looking statements by terminology including "anticipates," "believes," "can," "continue,"
  "could," "estimates," "expects," "intends," "may," "plans," "potential,"
  "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Although
  we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy.
  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined
  under "Risk Factors" or elsewhere in this prospectus and the documents incorporated by reference herein, which may cause
  our or our industry's actual results, levels of activity, performance or achievements expressed or implied by these forward-looking
  statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time
  to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the
  extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any
  forward-looking statements.
  We have based these forward-looking
  statements largely on our current expectations and projections about future events and financial trends that we believe may affect
  our financial condition, results of operations, business strategy, short term and long term business operations, and financial
  needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ
  materially from those reflected in the forward looking statements. Factors that could cause or contribute to such differences
  include, but are not limited to, those discussed in this prospectus, and in particular, the risks discussed below and under the
  heading "Risk Factors" and those discussed in other documents we file with the Securities and Exchange Commission (the
  "Commission" or the "SEC"). This prospectus should be read in conjunction with the consolidated financial
  statements as of and for the years ended December 31, 2022 and December 31, 2021, and related notes thereto, incorporated by
  reference into this prospectus. We undertake no obligation to revise or publicly release the results of any revision to these
  forward-looking statements, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking
  events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from
  those anticipated or implied in the forward-looking statement. You should not place undue reliance on any forward-looking statement,
  each of which applies only as of the date of this prospectus. You are advised, however, to consult any further disclosures we make
  on related subjects in our reports on Forms 10-K, 10-Q and 8-K filed with the Commission after the date of this prospectus.
  ii
  PROSPECTUS SUMMARY
  This summary highlights selected information
  contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in
  our Company. You should carefully read the entire prospectus, including all documents incorporated by reference herein. In particular,
  attention should be directed to our "Risk Factors," "Information with Respect to the Company," "Management's
  Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements and related notes thereto
  contained herein or otherwise incorporated by reference hereto, before making an investment decision.
  All references to "we," "us,"
  "our," and the "Company" mean Relmada Therapeutics, Inc. and its subsidiary Relmada Therapeutics, Inc. (Delaware).
  Business Overview
  Relmada Therapeutics,
  Inc. (Relmada or the Company, we or us) (a Nevada corporation), is a clinical-stage biotechnology company focused on the development
  of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone an isomer of
  methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous
  system (CNS) diseases and other disorders.
  Our lead product candidate,
  esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. On October
  15, 2019, we reported top-line data from study REL-1017-202. This was a double-blind, placebo-controlled Phase 2 clinical trial evaluating
  the safety, tolerability and efficacy of two oral doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment
  in patients with major depressive disorder (MDD), who experienced an inadequate response to 1 to 3 adequate antidepressant treatments
  with an antidepressant medication.
  Phase 2 Clinical
  Trial
  In the REL-1017-202
  study, 62 subjects, with an average age of 49.2 years, with an average Hamilton Depression Rating Scale score of 25.3 and an average
  Montgomery-Asberg Depression Rating Scale (MADRS) score of 34.0 (severe depression), were randomized. Other demographic characteristics
  were balanced across all arms. After an initial screening period, subjects were randomized to one of three arms: placebo, REL-1017 25
  mg or REL-1017 50 mg, in addition to stable background antidepressant therapy. Subjects in the REL-1017 treatment arms received one loading
  dose of either 75 mg (25 mg arm) or 100 mg (50 mg arm) of REL-1017. Subjects were treated inpatient for 7 days and discharged home at
  Day 9. They returned for follow-up visits at Day 14 and Day 21. Efficacy was measured on Days 2, 4 and 7 in the dosing period and on
  Day 14, one week after treatment discontinuation. 61 subjects received all treatment doses and were included in the per-protocol population
  (PPP) treatment analysis; 57 subjects completed all visits. All 62 randomized subjects were part of the intention-to-treat (ITT) analysis.
  No differences were observed between the ITT and PPP analyses and results.
  We observed that subjects
  in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement on all efficacy measures tested
  as compared to subjects in the placebo group, including: MADRS; the Clinical Global Impression – Severity (CGI-S) scale; the Clinical
  Global Impression – Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ).
  Improvements on the
  MADRS endpoint appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation,
  with P values< 0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0.
  Similar findings emerged from the CGI-S and CGI-I scales.
  The study also confirmed
  the tolerability profile of REL-1017, which was observed in the Phase 1 studies. Subjects experienced only mild and moderate adverse
  events (AEs), and no serious adverse events, without significant differences between placebo and treatment groups. The AEs observed in
  the Phase 2a clinical study were of the same nature as those observed in the Phase 1 clinical studies of d-Methadone, and there was no
  evidence of either treatment induced psychotomimetic and dissociative AEs or withdrawal signs and symptoms upon treatment discontinuation.
  1
  Phase 3 Program
  On December 20, 2020,
  Relmada announced that the first patient had been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company's lead
  product candidate, REL-1017, as an adjunctive treatment for MDD.
  On April 1, 2021, Relmada
  announced the initiation of RELIANCE II, the second of two sister pivotal Phase 3 clinical trials (RELIANCE I and RELIANCE II) for the
  Company's lead product candidate, REL-1017, as an adjunctive treatment for MDD.
  On October 4, 2021,
  Relmada announced the initiation of RELIANCE III study, a monotherapy trial for the Company's lead product candidate, REL-1017.
  On August 9, 2022, Relmada
  announced that the FDA granted Fast Track designation to REL-1017 as a monotherapy for the treatment of MDD.
  On October 13, 2022,
  Relmada announced that its RELIANCE III study, evaluating REL-1017 in the monotherapy setting for MDD, did not achieve its primary endpoint,
  which was a statistically significant improvement in depression symptoms compared to placebo as measured by MADRS on Day 28. In the study,
  the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected
  placebo response.
  On December 7, 2022,
  Relmada announced that its RELIANCE I study, evaluating REL-1017 as an adjunctive treatment for MDD, did not achieve its primary endpoint,
  which was a statistically significant improvement in depression symptoms compared to placebo as measured by MADRS on Day 28. In the study,
  the REL-1017 treatment arm (n= 113) showed a MADRS reduction of 15.1 points at Day 28 versus 12.9 points for the placebo arm (n=114),
  which is a clinically meaningful difference of 2.2 points on the MADRS. The study also showed a nominally statistically significant difference
  in the response rate, with a response rate of 39.8% in the REL-1017 arm vs 27.2% in the placebo arm (p<0.05).
  Patients who complete
  the RELIANCE trials are eligible to rollover into the long-term, open-label study, which also is expected to include subjects who had
  not previously participated in a REL-1017 clinical trial.
  In addition, in order
  to support potential regulatory submissions seeking approval for REL-1017 as monotherapy and adjunctive treatment, the FDA confirmed
  that, based on what is known at this time, Relmada will not be required to conduct a two-year carcinogenicity study of REL-1017, as sufficient
  clinical data have been generated to date. The FDA also confirmed that Relmada does not need to conduct a Thorough QT analysis (TQT)
  cardiac study in humans to support cardiac safety in potential regulatory submissions for REL-1017, as the data provided so far and the
  data generated by the Phase 3 program will be adequate to evaluate the cardiac safety profile of REL-1017.
  Human Abuse Potential (HAP) Studies
  Top-line Results - Oxycodone:
  On July 27, 2021, Relmada
  announced top-line results that showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg, the therapeutic, supratherapeutic and
  maximum tolerated doses (MTD), respectively, tested in recreational opioid users, demonstrated a highly statistically significant difference
  vs. the active control drug, oxycodone 40 mg. The study's primary endpoint was a measure of "likability" with the subjects
  rating the maximum effect (or Emax) for Drug Liking "at the moment", using a 1-100 bipolar rating scale (known as a visual
  analog scale or VAS), with 100 as the highest likability, 50 as neutral (placebo-like), and 0 the highest dislike. In summary, all tested
  doses of REL-1017, including the 150 mg MTD, showed a highly statistically significant difference in abuse potential versus oxycodone
  with p-values less than 0.05. Consistent results were seen for the secondary endpoints. Additionally, all REL-1017 doses including 150
  mg (6 times the therapeutic dose and MTD) were statistically equivalent to placebo (p<0.05). These results support the lack of opioid
  effects of REL-1017.
  Top-line Results - Ketamine:
  On February 23, 2022,
  Relmada announced top-line results that showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg, the therapeutic, supratherapeutic
  and MTD, respectively) tested in recreational drug users, demonstrated a substantial (30+ points) and statistically significant difference
  vs. the active control drug, intravenous ketamine 0.5 mg/kg over 40 minutes, and, importantly, were statistically equivalent to placebo.
  The study's primary endpoint was a measure of "likability" with the subjects rating the maximum effect (or Emax) for
  Drug Liking "at this moment", using a 1-100 bipolar rating scale (known as a visual analog scale or VAS), with 100 as the
  highest likability, 50 as neutral (placebo-like), and 0 the highest dislike. Consistent results are seen for the secondary endpoints.
  2
  Key Upcoming Anticipated Milestones
  We expect multiple key
  milestones over the next 12-18 months. These include:
  ●
  Results of RELIANCE II,
      the second of two adjunctive MDD trials, in the first half of 2024.
  ●
  Initiation of a new Phase
      III adjunctive MDD trial in mid-2023 with completion anticipated in the second half of 2024.
  ●
  Results of
      RELIANCE – OLS (Long-term, Open-label) study in MDD in mid-2023.
  Our Development Program
  Esmethadone (d-Methadone,
  dextromethadone, REL-1017) as a treatment for MDD
  Background
  In 2020, the National
  Institute of Mental Health (NIMH) estimated that 21.0 million adults aged 18 or older in the United States had at least one major depressive
  episode in the past year. According to data from nationally representative surveys supported by NIMH, only about half of Americans diagnosed
  with major depression in a given year receive treatment. Of those receiving treatment with as many as four different standard antidepressants,
  33% of drug-treated depression patients do not achieve adequate therapeutic benefits according to the Sequenced Treatment Alternatives
  to Relieve Depression (STAR*D) trial published in the American Journal of Psychiatry.
  In
  addition to the high failure rate, only two of the marketed products for depression, esketamine (marketed by Johnson and Johnson as Spravato®),
  an in-clinic nasal spray treatment, and dextromethorphan-bupropion (marketed by Axsome as Auvelity
  ä
  ),
  can demonstrate rapid antidepressant effects, while the other currently approved products can take two to eight weeks to show activity.
  The urgent need for improved, faster acting antidepressant treatments is underscored by the fact that severe depression can be life-threatening,
  due to heightened risk of suicide.
  Esmethadone Overview
  and Mechanism of Action
  Esmethadone's
  mechanism of action, as a low affinity, non-competitive NMDA channel blocker or antagonist, is fundamentally differentiated from most
  currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively with standard, FDA-approved antidepressants.
  Working through the same brain mechanisms as ketamine and esketamine but potentially lacking their adverse side effects, esmethadone
  is being developed as a rapidly acting, oral agent for the treatment of depression and potentially other CNS conditions.
  In chemistry an enantiomer,
  also known as an optical isomer, is one of two stereoisomers that are mirror images of each other that are non-superimposable (not identical),
  much as one's left and right hands are the same except for being reversed along one axis. A racemic compound, or racemate, is one
  that has equal amounts of left- and right-handed enantiomers of a chiral molecule. For racemic drugs, often only one of a drug's
  enantiomers is responsible for the desired physiologic effects, while the other enantiomer is less active or inactive.
  As a single isomer of
  racemic methadone, esmethadone has been shown to possess NMDA antagonist properties with virtually no traditional opioid or ketamine-like
  adverse events at the expected therapeutic doses. In contrast, racemic methadone is associated with common opioid side effects that include
  anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhea, drowsiness, and others. It has
  been shown that the left (levo) isomer, l-methadone, is largely responsible for methadone's opioid activity, while the right (dextro)
  isomer, esmethadone, at the currently therapeutic doses used in development is virtually inactive as an opioid while maintaining affinity
  for the NMDA receptor.
  NMDA receptors are present
  in many parts of the CNS and play important roles in regulating neuronal activity and promoting synaptic plasticity in brain areas important
  for cognitive functions such as executive function, learning and memory. Based on these premises, esmethadone could show benefits in
  several different CNS indications.
  Esmethadone (d-methadone,
  dextromethadone, REL-1017) in other indications
  While our current strategy
  is currently to focus on the further development of esmethadone as an adjunctive treatment of MDD, we may in the future re-commence testing
  of esmethadone as a monotherapy for MDD. In addition, we are evaluating other indications that Relmada may explore in the future, including
  restless leg syndrome and other glutamatergic system activation related diseases.
  3
  About This Offering
  This prospectus relates to the public offering,
  which is not being underwritten, by the Selling Stockholders listed in this prospectus, of up to 6,020,608 shares of our Common Stock.
  Of the shares being offered, 6,020,608 of which are currently issued and outstanding. The shares offered by this prospectus may be sold
  by the Selling Stockholders from time to time in the open market, through negotiated transactions or otherwise at market prices prevailing
  at the time of sale or at negotiated prices. We will receive none of the proceeds from the sale of the shares by the Selling Stockholders.
  We will bear all expenses of registration incurred in connection with this offering, but all selling and other expenses incurred by the
  Selling Stockholders will be borne by them.
  Stock Listing
  Our Common Stock is listed on The Nasdaq Global
  Select Market under the symbol "RLMD."
  Corporate Information
  Our principal executive offices are located
  at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134 and our telephone number is +1-646-876-3459. Our website address
  is
  www.relmada.com
  . The information contained therein or connected thereto shall not be deemed to be incorporated into
  this prospectus or the registration statement of which it forms a part. The information on our website is not part of this
  prospectus.
  4
  RISK FACTORS
  Investing in our securities involves a high degree
  of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described under
  the caption "Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K, , quarterly reports on Form 10-Q
  and current reports on Form 8-K that we have filed or will file with the SEC, which are incorporated by reference into this prospectus.
  Our business, affairs, prospects, assets, financial
  condition, results of operations and cash flows could be materially and adversely affected by these risks. For more information about
  our SEC filings, please see "Where You Can Find More Information."
  5
  USE OF PROCEEDS
  The shares which may be sold under this reoffer
  prospectus will be sold for the respective accounts of each of the Selling Stockholders listed herein (which includes our executive officers
  and directors). Accordingly, we will not realize any proceeds from the sale of the shares of our Common Stock. We will receive proceeds
  from the exercise of the options; however, no assurance can be given as to when or if any or all of the options will be exercised. If
  any options are exercised, the proceeds derived therefrom will be used for working capital and general corporate purposes. All expenses
  of the registration of the shares will be paid by us. See "Selling Stockholders" and "Plan of Distribution."
  6
  SELLING STOCKHOLDERS
  This reoffer prospectus relates to shares of
  Common Stock that are being registered for reoffer and resale by Selling Stockholders who have received or acquired, or may hereafter
  receive or acquire, the shares pursuant to the Plans. The Selling Stockholders may resell all, a portion, or none of the shares of Common
  Stock from time to time.
  The following table sets forth (a) the name
  of each Selling Stockholder; (b) the number of shares of Common Stock beneficially owned by each Selling Stockholder as of June 12,
  2023; (c) the maximum number of shares of Common Stock that each Selling Stockholder may offer for sale from time to time pursuant
  to this reoffer prospectus, whether or not the Selling Stockholder has any present intention to do so and whether or not such shares
  have previously been issued to the Selling Stockholders or may be issued in the future if at all; and (d) the number of shares of
  Common Stock and the percentage of the Company's outstanding Common Stock that would be beneficially owned by each Selling
  Stockholder assuming the sale of all of that Selling Stockholder's shares offered hereby. The percentage of our outstanding
  Common Stock to be owned by each Selling Stockholder assuming the sale of all of that Selling Stockholder's shares offered
  hereby is based on 30,099,203 shares of Common Stock issued and outstanding as of June 12, 2023. All information with respect to
  beneficial ownership has been furnished by the Selling Stockholders.
  Beneficial ownership is determined in accordance
  with the rules of the Commission and generally includes voting or investment power with respect to securities. Options to purchase and
  rights to receive shares of Common Stock that are currently exercisable or vested, or which are exercisable or vest within 60 days of
  the date of this prospectus are deemed to be outstanding and to be beneficially owned by the person holding such options for the purpose
  of computing the percentage ownership of any other person. Shares of restricted stock, whether vested or unvested, are deemed to be outstanding
  and to be beneficially owned by the person holding such restricted stock for the purpose of computing the percentage ownership of such
  person and are treated as outstanding for the purpose of computing the percentage ownership of each other person.
  Information concerning the identities of the
  Selling Stockholders, the number of shares that may be sold by each Selling Stockholder and information about the shares beneficially
  owned by the Selling Stockholders may from time to time be updated in supplements to this reoffer prospectus, which will be filed with
  the SEC in accordance with Rule 424(b) of the Securities Act if and when necessary. The names of persons selling shares under this reoffer
  prospectus and the amount of such shares are set forth below to the extent we presently have such information. However, other affiliate
  Selling Stockholders may elect to sell shares pursuant to this reoffer prospectus as they receive them from time to time.
  7
  The address of each Selling Stockholder is c/o
  Relmada Therapeutics, Inc., 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, Florida 33134.
  Number of Shares Beneficially
  Owned Prior to Offering (1)
  Number of
  Shares Being
  Number of Shares Beneficially
  Owned After Offering (1)
  Selling Stockholder
  Number
  Percent (%)
  Offered
  Number
  Percent (%)
  Sergio Traversa
  1,795,114
  5.7
  %
  1,994,722
  144,024
  *
  %
  Maged Shenouda
  895,625
  2.9
  1,035,289
  2,228
  *
  Charles Ence
  494,822
  1.6
  1,040,597
  -
  *
  Cedric O'Gorman
  60,120
  *
  400,000
  10,121
  *
  Charles Casamento
  449,551
  1.5
  300,000
  -
  *
  Paul Kelly
  796,511
  2.6
  450,000
  187,295
  *
  Eric Schmidt
  412,500
  1.4
  300,000
  100,000
  *
  John Glasspool
  312,500
  1.0
  300,000
  -
  *
  Fabiana Fedeli
  -
  *
  200,000
  -
  *
  Totals
  5,216,743
  17.3
  %
  6,020,608
  443,668
  *
  %
  *
  less
                                              than 1%
  (1)
  The
                                              securities "beneficially owned" by a person are determined in accordance with
                                              the definition of "beneficial ownership" set forth in the rules and regulations
                                              promulgated under the Exchange Act, and accordingly, may include securities owned by and
                                              for, among others, the spouse and/or minor children of an individual and any other relative
                                              who has the same home as such individual, as well as other securities as to which the individual
                                              has or shares voting or investment power or which such person has the right to acquire within
                                              60 days of June 12, 2023 pursuant to the exercise of options, or otherwise. Beneficial ownership
                                              may be disclaimed as to certain of the securities.
  8
  PLAN OF DISTRIBUTION
  The shares of Common Stock covered by this reoffer
  prospectus are being registered by the Company for the account of the Selling Stockholders.
  The shares of Common Stock offered may be sold
  from time to time directly by or on behalf of each Selling Stockholder in one or more transactions on the Nasdaq Global Select Market
  or any other stock exchange on which the Common Stock may be listed at the time of sale, in privately negotiated transactions, or through
  a combination of such methods, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at
  fixed prices (which may be changed) or at negotiated prices. The Selling Stockholders may sell shares through one or more agents, brokers
  or dealers or directly to purchasers. Such brokers or dealers may receive compensation in the form of commissions, discounts or concessions
  from the Selling Stockholders and/or purchasers of the shares or both. Such compensation as to a particular broker or dealer may be in
  excess of customary commissions.
  The Selling Stockholders may use any one or more
  of the following methods when disposing of Common Stock or interests therein:
  ●
  ordinary
                                              brokerage transactions and transactions in which the broker-dealer solicits purchasers;
  ●
  block
                                              trades in which the broker-dealer will attempt to sell the Common Stock as agent, but may
                                              position and resell a portion of the block as principal to facilitate the transaction;
  ●
  purchases
                                              by a broker-dealer as principal and resale by the broker-dealer for its account;
  ●
  an
                                              exchange distribution in accordance with the rules of the applicable exchange;
  ●
  privately
                                              negotiated transactions;
  ●
  short
                                              sales effected after the date the registration statement of which this reoffer prospectus
                                              is a part is declared effective by the SEC;
  ●
  through
                                              the writing or settlement of options or other hedging transactions, whether through an options
                                              exchange or otherwise;
  ●
  broker-dealers
                                              may agree with the Selling Stockholders to sell a specified number of such Common Stock at
                                              a stipulated price per share;
  ●
  a
                                              combination of any such methods of sale; and
  ●
  any
                                              other method permitted by applicable law.
  The Selling Stockholders may, from time to time,
  pledge or grant a security interest in some or all of the Common Stock owned by them and, if they default in the performance of their
  secured obligations, the pledgees or secured parties may offer and sell the common stock, from time to time, under this reoffer prospectus,
  or under an amendment to this reoffer prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the
  list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this reoffer
  prospectus. The Selling Stockholders also may transfer the Common Stock in other circumstances, in which case the transferees, pledgees
  or other successors in interest will be the selling beneficial owners for purposes of this reoffer prospectus.
  In connection with the sale of our Common Stock
  or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
  which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The Selling Stockholders
  may also sell our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock
  to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
  broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such
  broker-dealer or other financial institution of Common Stock offered by this reoffer prospectus, which shares such broker-dealer or other
  financial institution may resell pursuant to this reoffer prospectus (as supplemented or amended to reflect such transaction).
  9
  In connection with their sales, a Selling Stockholder
  and any participating broker or dealer may be deemed to be "underwriters" within the meaning of the Securities Act, and any
  commissions they receive and the proceeds of any sale of shares may be deemed to be underwriting discounts and commissions under the
  Securities Act.
  We are bearing all costs relating to the registration
  of the shares of Common Stock. Any commissions or other fees payable to brokers or dealers in connection with any sale of the shares
  will be borne by the Selling Stockholders or other party selling such shares. Sales of the shares must be made by the Selling Stockholders
  in compliance with all applicable state and federal securities laws and regulations, including the Securities Act.
  In addition to any shares sold hereunder, Selling
  Stockholders may sell shares of Common Stock in compliance with Rule 144. There is no assurance that the Selling Stockholders will sell
  all or a portion of the Common Stock offered hereby.
  The Selling Stockholders may agree to indemnify
  any broker, dealer or agent that participates in transactions involving sales of the shares against certain liabilities in connection
  with the offering of the shares arising under the Securities Act.
  We have notified the Selling Stockholders of
  the need to deliver a copy of this reoffer prospectus in connection with any sale of the shares.
  LEGAL MATTERS
  Certain legal matters relating to the validity
  of the issuance of Common Stock in this offering are being passed upon for us by Sichenzia Ross Ference LLP, New York, New York.
  EXPERTS
  The financial statements incorporated by reference
  into this prospectus have been so included in reliance on the report of Marcum LLP, an independent registered public accounting firm,
  related to the consolidated financial statements as of December 31, 2022 and 2021, and each of the two years in the period
  ended December 31, 2022, given on the authority of said firm as experts
  in auditing and accounting.
  10
  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
  We are incorporating by reference certain information
  that we have filed with the Commission under the informational requirements of the Exchange Act, which means that we disclose important
  information to you by referring to another document filed separately with the Company. The information contained in the documents we
  are incorporating by reference is considered to be a part of this reoffer prospectus, and the information that we later file with the
  SEC will automatically update and supersede the information contained or incorporated by reference in this reoffer prospectus.
  The following documents filed with the SEC are
  incorporated by reference in this reoffer prospectus:
  ●
  Our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2022, filed with the Commission on March 23, 2023;
  ●
  Our
                                              Quarterly Report on
  Form 10-Q
  for the quarterly period ended March 31, 2023, filed
                                              with the Commission on May 11, 2023;
  ●
  Our
                                              Current Reports on Form 8-K filed with the Commission on
  January 5, 2023
  ,
  January 17, 2023
  ,
  April 19, 2023
  ,
  May 15, 2023
  ,
  May 25, 2023
  ;
  ●
  Our
                                              Definitive Proxy Statement on
  Schedule 14A
  filed with the Commission on March 31,
                                              2023; and
  ●
  The
                                              description of certain capital stock contained in our Registration Statement on
  Form 8-A
  filed on October 8, 2019, as it may further be amended from time to time.
  All documents filed with the Commission by us
  pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this reoffer prospectus and prior to the
  termination of the offering relating to this reoffer prospectus (other than such portions and exhibits of the respective filings that
  were furnished pursuant to Items 2.02 or 7.01 of Current Reports on Form 8-K and not deemed filed under the Exchange Act) will be deemed
  to be incorporated by reference into this reoffer prospectus and to be a part of this reoffer prospectus from the date of filing of those
  documents. Any statement incorporated or deemed to be incorporated by reference into this reoffer prospectus will be deemed to be modified,
  replaced or superseded for purposes of this reoffer prospectus to the extent that a statement contained in this Reoffer Prospectus or
  in any other subsequently filed document, that also is or is deemed to be incorporated by reference into this reoffer prospectus modifies,
  replaces or supersedes that statement. Any statement so modified, replaced or superseded will be deemed, except as so modified, replaced
  or superseded, to constitute a part of this reoffer prospectus.
  WHERE YOU CAN FIND MORE INFORMATION
  This reoffer prospectus refers to certain documents
  that are not presented herein or delivered herewith. Such documents are available to any person, including any beneficial owner of our
  shares, to whom this reoffer prospectus is delivered upon oral or written request, without charge. Requests for such documents should
  be directed to Investor Relations, Relmada Therapeutics, Inc., 2222 Ponce de Leon Blvd, Floor 3, Coral Gables, Florida 33134. Please
  note that additional information can be obtained from our website at
  www.relmada.com
  .
  We file annual and special reports and other information
  with the SEC. Certain of our SEC filings are available over the Internet at the SEC's web site at
  http://www.sec.gov
  .
  You may also read and copy any document we file with the SEC at its public reference facilities:
  Public Reference Room Office 100 F Street, N.E.
  Room 1580
  Washington, D.C. 20549
  You may also obtain copies of the documents at
  prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Callers
  in the United States can also call (202) 551-8090 for further information on the operations of the public reference facilities.
  11
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3.
  Incorporation of
  Documents by Reference.
  The following documents filed by the Registrant
  with the Commission are incorporated herein by reference (excluding any portions of such documents that have been "furnished"
  but not "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act")):
  ●
  Our Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2022, filed with the Commission on March 23, 2023;
  ●
  Our
                                              Quarterly Report on
  Form 10-Q
  for the quarterly period ended March 31, 2023, filed
                                              with the Commission on May 11, 2023;
  ●
  Our
                                              Current Reports on Form 8-K filed with the Commission on
  January 5, 2023
  ,
  January 17, 2023
  ,
  April 19, 2023
  ,
  May 15, 2023
  ,
  May 25, 2023
  ;
  ●
  Our
                                              Definitive Proxy Statement on
  Schedule 14A
  filed with the Commission on March 31,
                                              2023; and
  ●
  The
                                              description of certain capital stock contained in our Registration Statement on
  Form 8-A
  filed on October 8, 2019, as it may further be amended from time to time.
  In addition, all documents subsequently filed
  by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of the post-effective amendment
  to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining
  unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing
  of such documents.
  Any statement contained in a document incorporated
  or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement
  to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to
  be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be
  deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  Under no circumstances will any information filed
  under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the
  contrary.
  You may request a copy of these filings, at no
  cost, by writing or telephoning the Registrant at:
  880 Third Avenue
  2222 Ponce de Leon Blvd., Floor 3
  Coral Gables, FL 33134
  Telephone: 212-547-9591
  Attn: Investor Relations
  You should rely only on the information provided
  or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide
  you with different information. You should not assume that the information in this Registration Statement or any related prospectus is
  accurate as of any date other than the date on the front of the document.
  II-
  1
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and
  Counsel.
  Not applicable.
  Item 6. Indemnification of Directors
  and Officers.
  The Registrant is a Nevada corporation and generally
  governed by the Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes, or NRS.
  Section 78.138 of the NRS provides that, unless
  the corporation's Articles of Incorporation provide otherwise, a director or officer will not be individually liable unless it
  is proven that (i) the director's or officer's acts or omissions constituted a breach of his or her fiduciary duties, and
  (ii) such breach involved intentional misconduct, fraud, or a knowing violation of the law. Our Articles of Incorporation provide that
  no director or officer shall be personally liable to the corporation or any of its stockholders for damages for any breach of fiduciary
  duty as a director or officer except for liability of a director or officer for (i) acts or omissions involving intentional misconduct,
  fraud, or a knowing violation of law or (ii) payment of dividends in violation of Section 78-300 of the NRS.
  Section 78.7502 of the NRS permits a company
  to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred
  in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i) is not liable pursuant
  to NRS 78.138, or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the
  best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer
  or director was unlawful. Section 78.7502 of the NRS also precludes indemnification by the corporation if the officer or director has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable to the corporation or for amounts paid
  in settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the
  person is fairly and reasonably entitled to indemnity for such expenses and requires a corporation to indemnify its officers and directors
  if they have been successful on the merits or otherwise in defense of any claim, issue, or matter resulting from their service as a director
  or officer.
  Section 78.751 of the NRS permits a Nevada company
  to indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding
  as they are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board members,
  or by independent legal counsel. Section 78.751 of NRS requires a corporation to advance expenses as incurred upon receipt of an undertaking
  by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that
  such officer or director is not entitled to be indemnified by the company if so provided in the corporations articles of incorporation,
  bylaws, or other agreement. Section 78.751 of the NRS further permits the company to grant its directors and officers additional rights
  of indemnification under its articles of incorporation, bylaws, or other agreement.
  Item 7. Exemption from Registration Claimed.
  Not applicable.
  Item 8. Exhibits.
  The Exhibits to this Registration Statement are
  listed in the Exhibit Index to this Registration Statement, which Exhibit Index is incorporated herein by reference.
  II-
  2
  Item 9. Undertakings.
  (a)
  The undersigned Registrant hereby undertakes:
  (1)
  To file, during any period in which offers or sales are being
  made, a post-effective amendment to the Registration Statement:
  (i)
  to include any prospectus required by Section 10(a)(3)
  of the Securities Act;
  (ii)
  to reflect in the prospectus any facts or events arising
  after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in
  the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing,
  any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
  was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
  filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change
  in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration
  Statement; and
  (iii)
  to include any material information with respect to the plan
  of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration
  Statement.
  provided, however
  , that paragraphs
  (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a
  post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant
  to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
  (2)
  That, for the purpose of determining any liability under
  the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
  offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (3)
  To remove from registration by means of a post-effective
  amendment any of the securities being registered which remain unsold at the termination of the offering.
  (b)
  The undersigned Registrant hereby undertakes that, for purposes
  of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a)
  or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant
  to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.
  (c)
  Insofar as indemnification for liabilities arising under the
  Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
  or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as
  expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
  with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
  expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  3
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
  S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
  City of New York, State of New York, on this 21st day of June, 2023
  Relmada Therapeutics, Inc.
  By:
  /s/ Sergio
      Traversa
  Sergio Traversa
  Chief Executive Officer and (Duly Authorized Officer
      and Principal Executive Officer)
  By:
  /s/ Maged
      Shenouda
  Maged Shenouda
  Chief Financial Officer
  (Principal Financial Officer)
  POWER OF ATTORNEY
  Each of the undersigned directors and officers
  of Relmada Therapeutics, Inc., a Nevada corporation, do hereby constitute and appoint Sergio Traversa the undersigned's true and
  lawful attorney and agent, with full power of substitution and resubstitution in each, to do any and all acts and things in our name
  and on our behalf in our respective capacities as directors and officers and to execute any and all instruments for us and in our names
  in the capacities indicated below, which said attorneys and agents, or either one of them, may deem necessary or advisable to enable
  said corporation to comply with the Securities Act, as amended, and any rules, regulations and requirements of the Securities and Exchange
  Commission, in connection with this registration statement, including specifically, but without limitation, power and authority to sign
  for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto,
  and each of the undersigned does hereby ratify and confirm all that said attorneys and agents, or either one of them or any substitute,
  shall do or cause to be done by virtue hereof. This Power of Attorney may be executed in any number of counterparts.
  Pursuant to the requirements of the Securities
  Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
  Signature
  Title
  Date
  /s/ Charles Ence
  Chief Accounting and Compliance Officer
  June 21, 2023
  Charles Ence
  (Principal Accounting Officer)
  /s/ Charles Casamento
  Director, Chairman of the Board
  June 21, 2023
  Charles Casamento
  /s/ Paul Kelly
  Director
  June 21, 2023
  Paul Kelly
  /s/ John Glasspool
  Director
  June 21, 2023
  John Glasspool
  /s/ Eric Schmidt
  Director
  June 21, 2023
  Eric Schmidt
  /s/ Fabiana Fedeli
  Director
  June 21, 2023
  Fabiana Fedeli
  II-
  4
  INDEX TO EXHIBITS
  Exhibit
      No.
  Description
  3.1
  Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 filed with the SEC on November 13, 2012).
  3.2
  Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Report on Form 8-K filed with the SEC on May 19, 2014).
  3.3
  Nevada Certificate of Amendment to Articles of Incorporation, effective May 30, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on June 2, 2014).
  3.4
  Nevada Certificate of Amendment to Articles of Incorporation, effective July 8, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on July 14, 2014).
  3.5
  Nevada Certificate of Amendment to Articles of Incorporation, effective February 12, 2015 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed with the SEC on February 13, 2015).
  3.6
  Nevada Certificate of Change Pursuant to NRS 78,209, effective August 11, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on August 10, 2015).
  3.7
  Second Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 of Relmada's Form 8-K filed with the SEC on November 25, 2015).
  3.8
  Certificate of Amendment to Articles of Incorporation, dated April 12, 2019 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on May 14, 2019).
  3.9
  Nevada Certificate of Change Pursuant to NRS 78.209, effective September 26, 2019 (incorporated by reference to Exhibit 3.1 of Relmada's Form 8-K filed with the SEC on September 27, 2019).
  3.10
  Certificate of Amendment to Articles of Incorporation, dated September 22, 2022 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on September 22, 2022).
  4.1
  Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 2, 2015).
  5.1
  Opinion of Sichenzia Ross Ference LLP*
  23.1
  Consent of Marcum LLP*
  23.2
  Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1)*
  24.1
  Power of Attorney (included on signature page)*
  99.1
  Relmada Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 20, 2021).
  99.2
  Relmada Therapeutics, Inc. 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 25, 2023).
  107
  Filing Fee Table
  *
  Filed
                                              herewith
  II-5